M A N U S C R I P T A C C E P T E D

. GLP-1 in vivo half-life is very short (~1.5min) due to its rapid proteolytic 4 degradation by dipeptidyl peptidase-IV (DPP-IV) and therefore long acting GLP-1 analogues such as 5 liraglutide, which have resistance to DPP-IV proteolysis, are developed for the treatment [3] . The 6 GLP-1R, which is a member of the family B G-protein coupled receptors (GPCRs), functions at the 7 cell surface by coupling to Gα s and Gα q pathways and causing extracellular signal-regulated kinase
8
(ERK) phosphorylation [2, 4] . Agonist-induced GLP-1R internalisation plays an important role in 9 glucose induced insulin secretion [5] . The GLP-1R internalises with similar kinetics in response to 10 GLP-1 and liraglutide stimulation [6] . However, the rate of GLP-1R recycling in cells treated with 11
liraglutide is slower than that in cells treated with GLP-1 [6] . Inhibition of the Gα q pathway, but not 12 the Gα s pathway, has recently been shown to significantly reduce agonist-induced GLP-1R
13
internalisation [7] . In the same study, chemical inhibitors of the Gα q pathway also shown to suppress
14
GLP-1-induced ERK phosphorylation, indicating that ERK phosphorylation acts downstream of the
15
Gα q pathway in GLP-1R internalisation [7] .
16
The extracellular N-terminal domain in many GPCRs is important for their biosynthetic 17 trafficking and maturation [2, 8] . Like other family B GPCRs, the GLP-1R contains an N-terminal 18 signal peptide (SP) and undergoes N-linked glycosylation, which are important for the newly 19 synthesised receptor cell surface expression [9] [10] [11] . We have recently demonstrated the importance of 20 SP cleavage, N-linked glycosylation and the hydrophobic region after the SP (HRASP) within the N-
21
terminus of the GLP-1R for its biosynthetic trafficking to the plasma membrane [12] . The intracellular
22
C-terminal domain of GPCRs plays a critical role in agonist-induced internalisation, desensitisation, 23 down regulation and arrestin signalling of the receptors [13] . Furthermore, the C-terminal region is 24 required for some GPCRs trafficking from the endoplasmic reticulum (ER) to the plasma membrane 25 [8] . The C-terminal domain of GPCRs is also known to interact with several intracellular proteins 26 involved in the internalisation of the receptor to intracellular signalling pathways [2, 8] .
27
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5 transmembrane (TM) 7 that associates with a number of intracellular proteins [14] . Additionally, many 4 GPCRs possess a PDZ binding site at the very end of the C-terminal domain, which interacts with the 5 PDZ domain of proteins required for biosynthetic trafficking of the receptor [2, 15] .
6
Agonist-induced GPCR internalisation is predominantly mediated by GPCR kinases 7 (GRKs), arrestins and clathrin coated pits. GRKs phosphorylate agonist-activated GPCRs to facilitate 8 the recruitment of arrestins, which target the GPCRs to clathrin-coated pits for rapid internalisation 9 [16] . In addition to its role in trafficking of newly synthesised GPCRs, the C-terminal domain can 10 interact with intracellular proteins involved in the internalisation of the receptor [14] . The tyrosine 11 motif (YXXΦ) within the C-terminus has been shown to associate with clathrin [17] . The β 3 -12 adrenoceptor (AR) contains a PXXP motif within the C-terminal domain that interacts with Src, which 
17
A dileucine (LL) motif within the C-terminal domain of some GPCRs has been shown to 18 promote some GPCRs internalisation by binding to adapter proteins [20] . GPCRs, such as the 19 neurokinin 1, β 2 -AR and the angiotensin II receptor (AT 2 R), require the conserved aromatic residue 20 tyrosine in the C-terminal domain for their internalisation [21] [22] [23] 
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6 present within the C-terminus of GLP-1R. Therefore, the aim of this study was to establish the 4 importance of residues and regions within the C-terminal domain of the human GLP-1R (hGLP-1R)
5
for the receptor biosynthetic trafficking to cell surface, activity and internalisation using a number of 6 C-terminal deletion and site-directed mutants. It was determined that residues 411-418 of the hGLP-
7
1R in the C-terminus are critical in targeting the receptor to the plasma membrane. M A N U S C R I P T A C C E P T E D 7 sequence followed by VSVG-epitope coding sequence, was cloned into pEGFP-N1 vector (Clontech), 3 as described previously [7] for expression as the N-terminus VSVG-tagged (after the SP) and the C-4 terminus GFP-tagged fusion protein in mammalian cells (SP-VSVG-hGLP-1R∆N23-GFP). The SP-
5
VSVG-hGLP-1R∆N23 with no GFP-tag and its C-terminal deletion constructs were generated by PCR 6 using sequence specific primers containing EcoRI restriction site (5' primer), SalI restriction site and 7 stop codon (3' primer) and SP-VSVG-hGLP-1R∆N23-GFP plasmid as the template, and cloning into 8 the same sites of pEGFP-N1. The E408A,V409A,Q410A mutation within the hGLP-1R was generated 9 using Quickchange II XL site-directed mutagenesis kit (Stratagene) and SP-VSVG-hGLP-1R∆N23-
10
GFP plasmid as the template [28] . The mutants with internal deletions (∆) within the C-terminus of 11 hGLP-1R were generated using Q5 site directed mutagenesis kit (New England Biolabs) and SP- 
22
Cells were lysed and cAMP levels in the cell lysates were estimated using the cAMP direct
23
immunoassay kit (Abcam) [7] . M A N U S C R I P T A C C E P T E D 
20
This was carried out as described previously [29, 30] . Briefly, proteins were separated in a SDS-
21
PAGE gel by electrophoresis and transferred onto polyvinylidene fluoride (PDVF) membrane.
22
Membranes were blocked with TBST (TBS with 0.1% tween 20) containing 5% milk powder probed with the anti-hGLP-1R mouse antibody or anti-GFP mouse antibody were stripped by using 4
Western blot stripping buffer (Thermo Scientific) and re-probed with the anti-VSVG rabbit antibody 5 (diluted 1:1000 in blocking buffer) to assess protein expression levels. Blots probed with the anti-6 pERK1/2 rabbit antibody were stripped and re-probed with the anti-ERK1/2 rabbit antibody (diluted 7 1:1000 in blocking buffer) to assess total ERK1/2. The HRP-conjugated anti-rabbit secondary 8 antibody (diluted 1:2500 in blocking buffer) was used as described above. 
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The importance of the C-terminus for hGLP-1R cell surface expression was determined using a 3 number of C-terminal deletion mutants, which contain the VSVG-epitope tag at the N-terminus after 4 the SP (Figure 1 ). However, three deletion mutations, ∆411-418, ∆419-430 and ∆431-450, and a site-5 directed mutant (E408A,V409A,Q410A), which has previously been shown to affect agonist binding 6 to the hGLP-1R [27], contain an additional GFP-tag at the C-terminus. We have shown previously that 7 the cAMP producing activity of the SP-VSVG-GFP construct (which contains both VSVG and GFP 8 tags) is similar to that of the hGLP-1R with no tag or either of the VSVG-tag or GFP-tag, indicating 9 that the attachment of the VSVG and GFP tags to the hGLP-1R had no effect on the activity of the 10 receptor [12] .
11
Lysates of HEK293 cells expressing some of the C-terminal mutants of hGLP-1R showed a 12 doublet of same intensity in immunoblotting (~55 kDa and ~35 kDa in size) with both the anti-hGLP-
13
1R and anti-VSVG antibodies, demonstrating no alterations in hGLP1-R protein expression by these 
4
To determine the effect of the C-terminal deletion and site-directed mutations on hGLP-1R 5 cell surface expression, these mutants were expressed in HEK293 cells and analysed for their cell 6 surface expression by ELISA ( Figure 3A ) and immunofluorescence ( Figure 3B ). The FL (463aa) and 7 the N450, N443, N440 and N430 deletion mutants showed identical cell surface expression when 8 assessed by ELISA (100%, 96.6 ± 2.2%, 97.1 ± 1.7%, 93.5 ± 3.7%, 97.0 ± 1.5%, p>0.05, respectively, 9 Figure 3A ). However, the mutant with the entire C-terminal domain deletion (N410) showed no cell 10 surface expression (0.1 ± 0.1%, p<0.001), demonstrating that the C-terminal domain is required for 11 hGLP-1R biosynthetic trafficking to the cell surface. These results also demonstrate that the last 33aa
12 within the C-terminus are not required for cell surface expression of the hGLP-1R. Therefore, these antibody. However, N410, ∆411-418 and E408A,V409A,Q410A mutants showed no cell surface 27 expression ( Figure 3B ). The reduction in cell surface expression of these mutants was not due to
The C-terminal domain mutations have no effect on hGLP-1R N-glycosylation 3
The hGLP-1R that is targeted to the cell surface (mature hGLP-1R) is N-glycosylated [9] [10] [11] . The 
15
However, the N410 deletion mutant, which do not express at cell surface, showed a single band at ~35
16
kDa in immunoblotting and a shift in that band mobility when treated with tunicamycin. This
17
suggested that the mutant is N-glycosylated to some extent and therefore loss of this mutant cell
18
surface expression may not be due to absence of N-linked glycosylation.
19
The SP-VSVG-GFP WT showed a doublet (~70 kDa and ∼85 The GLP-1R is a Gα s coupled GPCR and therefore the effect of C-terminal mutations on the receptor 
Further, the ∆431-450 mutant showed maximal cAMP production (3.5 ± 0.5 pmol/well, p>0.05) 20 similar to that of the SP-VSVG-GFP WT control (3.5 + 0.3 pmol/well). Additionally, the 21 E408A,V409A,Q410A mutant of the hGLP-1R showed very low cAMP production (0.6 ± 0.2 22 pmol/well, p<0.001), which is expected as this mutant does not target to the cell surface. Taken The C-terminal deleted and site-directed mutants of the hGLP-1R that show cell surface expression 5
were assessed for their effect on agonist-induced hGLP-1R internalisation by ELISA ( Figure 6A ) and 6 immunofluorescence ( Figure 6B ). Deleting 13aa (N450) from the end of the C-terminal domain had 7 no effect on agonist-induced internalisation (100.0 ± 1.0%, p>0.05). However, the N443, N440 and
8
N430 mutants all showed a significant reduction in agonist-induced internalisation compared to the FL significantly reduced agonist-induced internalisation of the hGLP-1R, as only 22.9 ± 5.3% (p<0.001)
13
of the receptor expressed at the cell surface was internalised. However, the ∆419-430 deletion had no 14 effect on agonist-induced hGLP-1R internalisation (111.9 ± 7.1%, p>0.05). These results were
15
confirmed by immunofluorescence ( Figure 6B ).
16
Upon activation by agonist binding, the GLP-1R is known to cause ERK1/2 phosphorylation
17
[34]. We have recently shown that the agonist-induced hGLP-1R internalisation is mediated by the
18
Gα q pathway and the phosphorylated ERK acts downstream of the Gα q pathway in hGLP-1R
19
internalisation [7] . Therefore, the C-terminal deletion mutants were assessed for their effect on 20 agonist-induced ERK1/2 phosphorylation ( Figure 7A-B) . The N410, ∆411-418 and
21
E408A,V409A,Q410A mutants, which show no cell surface expression, did not induce ERK1/2 22 phosphorylation (4.0 ± 1.5%, 6.7 ± 2.7% and 10.3 ± 0.6%, p<0.001, respectively). The hGLP-1R C-
23
terminal deletion mutants, N450, N443, N440 and N430, ERK1/2 phosphorylation inducing ability 24 correlated with their agonist-induced internalisation. Deletion of 13aa (N450) from the C-terminus of 25 hGLP-1R had no effect on agonist-induced ERK1/2 phosphorylation (103.6 ± 2.4%). However, the 26 hGLP-1R mediated ERK1/2 phosphorylation reduced with increasing deletion from the C-terminus of M A N U S C R I P T
A C C E P T E D 16
internalisation of the receptor, deletion of these residues (∆431-450) also reduced ERK1/2 4 phosphorylation mediated by the hGLP-1R (20.7 ± 3.1% [p<0.001]). Taken together, these results
5
demonstrate that residues 431-450 are essential for hGLP-1R internalisation and ERK1/2 6 phosphorylation.
8
Discussion
9
The C-terminal domain of many GPCRs plays a critical role in the receptor trafficking, agonist-10 induced internalisation, desensitisation, down regulation and arrestin signalling [13] . In this study,
11
several deletion and site-directed mutants of the hGLP-1R were generated to identify the distinct 12 regions within the C-terminal domain required for hGLP-1R biosynthetic trafficking, its Gα s coupling
13
(cAMP producing activity) and internalisation. Additionally, an E408A,V409A,Q410A mutant was 14 generated and assessed for its effect on hGLP-1R cell surface expression, as this mutation had 15 previously been shown to inhibit cAMP production of the hGLP-1R [27] .
16
The expression of GPCRs at the cell surface is essential for their functional response.
17
Reduced cell surface expression of the GLP-1R in pancreatic β-cells has been shown to contribute to 18 the impaired incretin effects in type 2 diabetes [35, 36] . Therefore, the mechanisms underlying newly 
21
The C-terminal domain of GPCRs is also known to interact with intracellular proteins to 
25
(mGluR) 7a and 7b and regulate P and Q type Ca 2+ channels [44] . In this study, the deletion of 26 residues 419-430 of the hGLP-1R has shown to impair agonist-induced cAMP production, suggesting 27 that this region is directly or indirectly involved in coupling the receptor to Gα s . It is also possible that
28
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18 differences would not be identified with the saturating agonist concentration used in this study.
4
However, a previous study suggested that deleting residues 419-435 of the hGLP-1R decreases the 5 agonist-induced cAMP production [27] . Taken together, the results of our study and a previous study 
12
The internalisation of GPCRs from the cell surface after agonist stimulation is required to
13
dampen the biological response, to recycle and resensitise the receptor through dephosphorylation, or
14
to propagate signals through novel signalling pathways [47] . Upon agonist stimulation, the by GRK2 has been shown to be required for internalisation of the receptor [54] . In this study, GLP-1-
10
induced ERK1/2 phosphorylation was also used as readout for hGLP-1R internalisation. This is 11 because the ERK1/2 phosphorylation, downstream of the Gα q pathway, has recently been shown to be 12 important for agonist-induced hGLP-1R internalisation [7] . Interestingly, residues 419-430 of the 13 hGLP-1R were important for stimulation of cAMP production with no negative effect on its 14 internalisation, which supports the our recent observations that the GLP-1R does not require cAMP 15 production for internalisation of the receptor [7] .
16
In this study, cAMP production and receptor internalisation of the hGLP-1R was 
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25 of the C-terminal domain on its cell surface expression, internalisation and activity. Schematic 4 view of the hGLP-1R C-terminal domain deletion and site-directed mutants used in this study. M A N U S C R I P T
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• Residues 411-418 in the C-terminus are critical for GLP-1R cell surface expression.
• Residues 419-430 within the C-terminus are important for the activity of GLP-1R.
• Residues 431-450 in the C-terminus are essential for GLP-1R internalisation.
